Previous studies have demonstrated that anergic CLL cells exhibit constitutive activation of ERK1/2 and NFAT211 as well as low or absent expression of ZAP70, CD38 and surface IgM9. This evidence concerns the gene MAPK3 and B-cell chronic lymphocytic leukemia.